DR. Reddy's Laboratories
- ISIN
- INE089A01031
- Instrument key
- NSE_EQ|INE089A01031
as of 21/11/2026, 1:56:02 pm
- Open
- ₹1,388.00
- Day high
- ₹1,400.00
- Day low
- ₹1,384.80
- Prev. close
- ₹1,400.90
- Volume
- 8.31 L
- VWAP
- ₹1,392.27
02/Price history
Price chart
5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
- Change · 5Y
- +48.80%934.30 → 1,390.20
- Period high
- ₹1,421.5019/8/2024
- Period low
- ₹730.8028/2/2022
- From high
- -2.20%+90.23% from low
- Avg volume
- 99.30 L260.16 Cr total
- Volatility · ann.
- 22.3%262 candles · 145 up / 117 down
Candle data262 rows of open, high, low, close and volumeShowHide
| 16 Nov 2026 | 1,383.00 | 1,406.10 | 1,368.70 | 1,390.20 | +0.52% | 37.40 | 54.92 L |
| 9 Nov 2026 | 1,375.00 | 1,404.00 | 1,369.30 | 1,380.00 | +0.36% | 34.70 | 60.06 L |
| 2 Nov 2026 | 1,352.00 | 1,385.00 | 1,336.70 | 1,370.00 | +1.33% | 48.30 | 91.18 L |
| 26 Oct 2026 | 1,260.00 | 1,363.70 | 1,224.00 | 1,352.00 | +7.30% | 139.70 | 1.88 Cr |
| 19 Oct 2026 | 1,232.00 | 1,252.00 | 1,212.70 | 1,229.50 | -0.20% | 39.30 | 66.03 L |
| 12 Oct 2026 | 1,197.00 | 1,250.70 | 1,196.90 | 1,233.00 | +3.01% | 53.80 | 84.44 L |
| 5 Oct 2026 | 1,198.00 | 1,222.80 | 1,167.20 | 1,197.00 | -0.08% | 55.60 | 1.03 Cr |
| 28 Sept 2026 | 1,211.60 | 1,252.80 | 1,194.90 | 1,206.20 | -0.45% | 57.90 | 1.54 Cr |
| 21 Sept 2026 | 1,185.00 | 1,222.00 | 1,185.00 | 1,201.00 | +1.35% | 37.00 | 87.30 L |
| 14 Sept 2026 | 1,163.70 | 1,207.50 | 1,133.90 | 1,185.00 | +1.83% | 73.60 | 82.46 L |
Historical price and volume data · Showing 1–10 of 262
03/Valuation & returns
Key ratios vs sector
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 193%
Price ÷ book value per share
Better than sector by 29%
Net income ÷ total assets
Better than sector by 303%
Net income ÷ shareholders' equity
Better than sector by 1902%
EBIT ÷ capital employed
Worse than sector by 44%
Liquid assets ÷ current liabilities
Worse than sector by 72%
Enterprise value ÷ EBITDA
Better than sector by 14%
04/Business
About the company
Sector: Pharmaceuticals
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
- ₹1,16,145 Cr
- $12.90B
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Standalone income statement
Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.
- Revenue · Sep 2026
- ₹5,790 Cr+3.82% vs Jun 2026
- Net profit · Sep 2026
- ₹696 Cr+71.93% vs Jun 2026
- Operating margin
- 15.6%was 8.9%
- Revenue CAGR · 4p
- 7.6%profit 97.3% · op 105.3%
| Revenue | 5,790 | 5,577 | 4,389 | 4,643 |
|---|---|---|---|---|
| Revenue growthreported | 3.8% | 27.1% | -5.5% | — |
| Operating profit | 901 | 497 | -305 | 104 |
| Operating profit growthreported | 81.3% | 262.7% | -393.2% | — |
| Operating marginderived | 15.6% | 8.9% | -7.0% | 2.2% |
| Net profit | 696 | 405 | -219 | 91 |
| Net profit growthreported | 71.9% | 284.5% | -342.2% | — |
| Net marginderived | 12.0% | 7.3% | -5.0% | 2.0% |
| EPS — basic₹/share, annual | — | — | 38.68 | — |
Figures in ₹ crore. Margin rows are computed from the reported values.
Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
| Revenue | 20,533 | 23,115 | 19,484 | 16,963 |
|---|---|---|---|---|
| Other Income | 1,690 | 1,003 | 862 | 591 |
| Total Revenue | 22,222 | 24,119 | 20,346 | 17,554 |
| Total Expenses | 17,971 | 16,883 | 14,555 | 13,688 |
| Profit Before Tax | 4,251 | 7,236 | 5,791 | 3,866 |
| Tax | 1,032 | 1,887 | 1,449 | 1,253 |
| Profit After Tax | 3,220 | 5,349 | 4,342 | 2,613 |
| EPS - Basic | 38.68 | 64.22 | 52.19 | 157.37 |
| EPS - Diluted | 38.64 | 64.13 | 52.09 | 157.03 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
06/Balance sheet
Standalone balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
- Total assets · Mar 2026
- ₹43,602 Cr+13.87% YoY
- Total liabilities
- ₹12,237 Cr
- Net worth
- ₹31,366 Cr
- Liabilities ÷ assets
- 28.1%lower means a lighter balance sheet
| Total assets | 43,602 | 38,291 | 30,359 | 25,375 |
|---|---|---|---|---|
| Total liabilities | 12,237 | 9,434 | 6,119 | 4,901 |
| Net worthderived | 31,366 | 28,857 | 24,241 | 20,474 |
| Liabilities ÷ assetsderived | 28.1% | 24.6% | 20.2% | 19.3% |
| Asset growthderived | 13.9% | 26.1% | 19.6% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
| Non-Current Assets | 25,079 | 21,788 | 12,543 | 11,587 |
|---|---|---|---|---|
| Current Assets | 18,523 | 16,503 | 17,816 | 13,788 |
| Total Assets | 43,602 | 38,291 | 30,359 | 25,375 |
| Current Liabilities | 11,143 | 8,652 | 5,538 | 4,440 |
| Net Current Asset | 7,381 | 7,851 | 12,278 | 9,349 |
| Non-Current Liabilities | 1,094 | 783 | 580 | 461 |
| Equity Capital | 31,366 | 28,857 | 24,241 | 20,474 |
| Total Equity & Liabilities | 43,602 | 38,291 | 30,359 | 25,375 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Standalone cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
- Operating · Mar 2026
- ₹4,661 Cr+10.31% YoY
- Investing
- -₹5,785 Cr
- Financing
- ₹1,117 Cr
- Free cash flow
- -₹1,124 Croperating + investing
| Operating activities | 4,661 | 4,225 | 3,450 | 5,053 |
|---|---|---|---|---|
| Operating changereported | 10.3% | 22.5% | -31.7% | — |
| Investing activities | -5,785 | -5,698 | -3,430 | -3,448 |
| Investing changereported | -1.5% | -66.1% | 0.5% | — |
| Financing activities | 1,117 | 1,591 | 68 | -2,697 |
| Financing changereported | -29.8% | 2235.8% | 102.5% | — |
| Net cash flowderived | -7 | 118 | 87 | -1,092 |
| Free cash flowoperating + investing | -1,124 | -1,473 | 19 | 1,605 |
Figures in ₹ crore.
Full annual line itemsProfit before tax through closing cash balanceShowHide
| Profit before tax | 4,251 | 7,236 | 5,791 | 3,866 |
|---|---|---|---|---|
| Income before WC changes | 4,742 | 8,050 | 6,393 | 4,912 |
| Change in Assets | 999 | -2,179 | -1,558 | 557 |
| Change in Liabilities | -134 | -60 | -66 | 367 |
| Change in WC | 866 | -2,239 | -1,624 | 924 |
| Cash flow from Operations | 4,661 | 4,225 | 3,450 | 5,053 |
| Cash flow from Investing | -5,785 | -5,698 | -3,430 | -3,448 |
| Cash flow from Financing | 1,117 | 1,591 | 68 | -2,697 |
| Total Cash Flow | -7 | 118 | 88 | -1,092 |
| Cash (Start of the year) | 320 | 201 | 112 | 1,160 |
| Cash (End of the year) | 338 | 320 | 201 | 112 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Corporate actions
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendFinal | ₹8.00 | 800.0% | 10 Jul 2026 | 10 Jul 2026 | 12 May 2026 |
10/Comparison
Peers & competitors
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| CIPLACipla Ltd | Pharmaceuticals | ₹1,415.00 | -0.25% | 14.84 L | ₹1,14,312 Cr | $12.70B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Company news
Articles published in the last seven days, paginated by the provider.
No news in the last seven days
Company news is available for a rolling one-week window.